These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38750006)

  • 1. Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer.
    Pan YC; Chu PY; Lin CC; Hsieh CY; Hsu WY; Shyur LF; Yang JC; Chang WC; Wu YC
    Mol Oncol; 2024 Aug; 18(8):1866-1884. PubMed ID: 38750006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity.
    Piaggi S; Raggi C; Corti A; Pitzalis E; Mascherpa MC; Saviozzi M; Pompella A; Casini AF
    Carcinogenesis; 2010 May; 31(5):804-11. PubMed ID: 20106899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated glutathione transferase omega-1 correlates with progression of urinary bladder carcinoma.
    Djukic T; Simic T; Pljesa-Ercegovac M; Matic M; Suvakov S; Coric V; Dragicevic D; Savic-Radojevic A
    Redox Rep; 2017 Nov; 22(6):486-492. PubMed ID: 28288548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione S-transferase omega 1 inhibition activates JNK-mediated apoptotic response in breast cancer stem cells.
    Manupati K; Debnath S; Goswami K; Bhoj PS; Chandak HS; Bahekar SP; Das A
    FEBS J; 2019 Jun; 286(11):2167-2192. PubMed ID: 30873742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor.
    Ramkumar K; Samanta S; Kyani A; Yang S; Tamura S; Ziemke E; Stuckey JA; Li S; Chinnaswamy K; Otake H; Debnath B; Yarovenko V; Sebolt-Leopold JS; Ljungman M; Neamati N
    Nat Commun; 2016 Oct; 7():13084. PubMed ID: 27703239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSTO1 confers drug resistance in HCT‑116 colon cancer cells through an interaction with TNFαIP3/A20.
    Paul S; Bhardwaj M; Kang SC
    Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype.
    Kotoh S; Naito S; Yokomizo A; Kohno K; Kuwano M; Kumazawa J
    J Urol; 1997 Mar; 157(3):1054-8. PubMed ID: 9072542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Cancer Effects and Tumor Marker Role of Glutathione
    Jou YC; Wang SC; Dia YC; Wang ST; Yu MH; Yang HY; Chen LC; Shen CH; Liu YW
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSTO1*C/GSTO2*G haplotype is associated with risk of transitional cell carcinoma of urinary bladder.
    Djukic T; Simic T; Radic T; Matic M; Pljesa-Ercegovac M; Suvakov S; Coric V; Pekmezovic T; Novakovic I; Dragicevic D; Savic-Radojevic A
    Int Urol Nephrol; 2015 Apr; 47(4):625-30. PubMed ID: 25716313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance.
    Tsuboi K; Bachovchin DA; Speers AE; Spicer TP; Fernandez-Vega V; Hodder P; Rosen H; Cravatt BF
    J Am Chem Soc; 2011 Oct; 133(41):16605-16. PubMed ID: 21899313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
    Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
    Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
    Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
    Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovatodiolide, isolated from Anisomeles indica, suppresses bladder carcinogenesis through suppression of mTOR/β-catenin/CDK6 and exosomal miR-21 derived from M2 tumor-associated macrophages.
    Wu ATH; Srivastava P; Yadav VK; Tzeng DTW; Iamsaard S; Su EC; Hsiao M; Liu MC
    Toxicol Appl Pharmacol; 2020 Aug; 401():115109. PubMed ID: 32544403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer.
    Huang C; Yang Y; Wang X; Chen S; Liu Z; Li Z; Tang X; Zhang Q
    Int J Biol Sci; 2024; 20(9):3570-3589. PubMed ID: 38993556
    [No Abstract]   [Full Text] [Related]  

  • 15. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
    Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
    J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.
    Deng X; Yang X; Cheng Y; Liu X; Li X; Zhao R; Qin C; Lu Q; Yin C
    Sci Rep; 2015 Sep; 5():14000. PubMed ID: 26354850
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
    Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway.
    Hong JH; Tong ZJ; Wei TE; Lu YC; Huang CY; Huang CY; Chiang CH; Jaw FS; Cheng HW; Wang HT
    Mol Cancer Ther; 2022 Jun; 21(6):1010-1019. PubMed ID: 35312783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
    Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
    Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.